Ginkgo Bioworks Holdings (DNA)vsInsmed Inc (INSM)
DNA
Ginkgo Bioworks Holdings
$7.36
+2.65%
HEALTHCARE · Cap: $415.51M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 256% more annual revenue ($606.42M vs $170.16M). DNA leads profitability with a -1.8% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
DNA
Avoid33
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
DNA carries more volatility with a beta of 1.59 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
DNA generates stronger free cash flow (-63M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering leader in the synthetic biology sector, utilizing advanced genetic engineering technologies to create customized bioengineered organisms for applications in pharmaceuticals, agriculture, and industrial biotech. Its proprietary platform significantly enhances cellular design for manufacturing, streamlining product development and production processes. Dedicated to addressing global challenges such as climate change and food security, Ginkgo is strategically positioned to influence a wide array of industries while driving sustainable innovation. With its commitment to bio-based solutions, the company is poised for robust growth in a rapidly evolving biotech landscape.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?